ArticleACS omega2025
Synthesis and Characterization of Q0-Eugenol Nanoemulsion for Drug Delivery to Breast and Hepatocellular Cancer Cell Lines.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Astragalus membranaceus polysaccharide (APs) and Eugenol: Multi-target Anti-inflammatory, Antioxidant, Antimicrobial, and anticancer effects validated by in Silico studies.Journal, genetic engineering & biotechnology · 2026Article
- Developing a QSPR model for Alzheimer's drugs using topological indices and M-polynomial: A computational study.Scientific reports · 2025Article
- Eugenol: An Insight Into the Anticancer Perspective and Pharmacological Aspects.Food science & nutrition · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is the second cause of death globally. The advent of nanoparticles has revolutionized drug delivery in cancer treatment. This study introduces a novel Q0-eugenol nanoemulsion designed for enhanced drug delivery. Synthesis of nanoemulsion was performed by the homogenization technique and ultrasonication for size reduction. DLS, FTIR, and UV-vis spectroscopy were used for characterization of Q0-eugenol nanoemulsion. MTT assay and flow cytometry assay were applied to determine the fibroblast, KPL1, and PLC/PRF/5 cell lines to consider the cell viability and apoptosis percentage, respectively. The oxidative status of Q0-eugenol nanoemulsion was evaluated by the ferric reducing antioxidant power assay and the thiobarbituric acid reactive substance assay. The zeta potential charge of eugenol and Q0-eugenol nanoemulsion formulation was equal to 45.1 and 22.7 mV, respectively. Eugenol nanoemulsion and Q0-eugenol nanoemulsion treatment exhibited antiproliferative effect against breast and liver cancer cell lines (
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.